An anticancer vaccine composition for transdermal administration for use in the induction of cellular immunity, comprising: (i) a HER2 / neu E75 peptide and / or a modified HER2 / neu E75 peptide； and (ii) a first stimulator of cellular immunity induction selected from a TLR ligand, a cyclic dinucleotide, a helper peptide, an immunomodulatory low molecular weight drug, a cyclooxygenase inhibitor, a prostaglandin receptor antagonist, a prostaglandin receptor agonist, a TSLP inhibitor, an acid inhibitor, an omega 3 fatty acid inhibitor, an acid inhibitor PPAR agonist, dopamine receptor antagonist, dopamine receptor agonist, histamine receptor agonist, histamine receptor antagonist, serotonin receptor agonist, serotonin receptor antagonist, vasopressin receptor antagonist, vasopressin receptor agonist, muscarinic receptor antagonist, muscarinic receptor agonist, adrenergic receptor antagonist, adrenergic receptor agonist, angiotensin agonist receptor agonist, agonist receptor agonist, GABA receptor agonist, agonist agonist ADP, leukotriene receptor antagonist, leukotriene receptor agonist, melatonin receptor agonist, agonist somatostatin receptor, cannabinoid receptor agonist, sphingosine 1-phosphate receptor agonist, glutamate metabotropic receptor agonist, phospholipase A2 inhibitor, TGF-β production inhibitor, Th2 cytokine inhibitor, and a combination of two or more thereof. 2. The anti-cancer vaccine composition for transdermal administration according to claim 1, wherein1. Композиция противораковой вакцины для трансдермального введения для применения в индукции клеточного иммунитета, содержащая:(i) пептид HER2/neu E75 и/или модифицированный пептид HER2/neu E75； и(ii) первый стимулятор индукции клеточного иммунитета, выбранный из лиганда TLR, циклического динуклеотида, хелперного пептида, иммуномодулирующего низкомолекулярного лекарственного средства, ингибитора циклооксигеназы, антагониста рецептора простагландина, агониста рецептора простагландина, ингибитора про
